Inventor

WHITTAKER MARK

GB74 patents

⚠️ This page may combine multiple inventors who share the name “WHITTAKER MARK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

WHITTAKER MARK

BRITISH BIOTECH PHARM

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Derivatives of succinamide and their use as metalloproteinase inhibitors

Metalloproteinase inhibitors

Amino acid derivatives as paf-receptor antagonists

4-(1H-2-methylimidazo[4,5-c]pyridinylmethyl)phenylsulphonamide derivatives as antagonist of PAF

Antibacterial agents

Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors

Imidazo (4,5-C) pyridine derivatives as PAF antagonists

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Metalloproteinase inhibitors

Hydroxamic acid derivatives as metalloproteinase inhibitors

Hexahydrofuro(2,3-b)furans as PAF antagonists

Antibacterial agents

Hydroxamic acid derivatives as antibacterials

Biphenyl ether heterobicyclic platelet activating factor antagonists

Antibacterial agents

Antibacterial agents

Imidazopyridine derivatives as dual histamine (H1) and platelet activating factor (PAF) antagonists

Heterocyclic sulfonamide derivatives as antagonists of PAF and angiotensin II

Metalloproteinase inhibitors

Derivatives of succinamide and their use as metalloproteinase inhibitor

Metalloproteinase inhibitors

BRITISH BIO TECHNOLOGY

Benzimidazole derivatives

Production of heterobicyclic containing benzene sulfonamides

Heterobicyclic containing benzene sulfonamides which are platelet activating factor antagonists

Carboxamide amino acid heterobicyclic paf antagonists

Certain sulfonamide heterobicyclic platelet activating factor antagonists

MIDDLEMISS DAVID

Treatment of CRTH2-mediated diseases and conditions

Treatment of CRTH2-mediated diseases and conditions

Treatment of CRTH2-mediated diseases and conditions

Treatment of CRTH2-mediated diseases and conditions

OXAGEN LTD

Compounds for the treatment of CRTH2-mediated diseases and conditions

Compounds having CRTH2 antagonist activity

Compounds having CRTH2 antagonist activity

ARMER RICHARD EDWARD

Compounds having CRTH2 antagonist activity

Compounds having CRTH2 antagonist activity

(unassigned)

Cargo securement system and tie down strap

NAEJA PHARMACEUTICALS INC

Substituted azetidin-2-ones as cysteine protease inhibitors

NAEJA PHARMACEUTICAL INC

Cysteine protease inhibitors

COGAN DEREK

Serotonin 5-HT2B receptor inhibitors